EREG Antibody

What is EREG and why are EREG antibodies important in research?

EREG (Epiregulin) is a member of the epidermal growth factor (EGF) family, functioning as a ligand for EGF receptor (EGFR) and ERBB4. It is a small polypeptide with a molecular weight of approximately 19 kilodaltons and may also be known as EPR, ER, and proepiregulin . EREG contributes to inflammation, wound healing, tissue repair, and oocyte maturation by regulating angiogenesis and vascular remodeling and by stimulating cell proliferation . In cancer research, EREG has emerged as a critical biomarker for treatment response and a potential therapeutic target due to its role in tumor progression and drug resistance .

EREG antibodies enable precise detection and quantification of EREG protein across multiple experimental platforms, facilitate the investigation of EGFR signaling pathways, and serve as building blocks for novel therapeutic approaches, particularly for cancers that overexpress EREG.

What are the key structural and functional characteristics of EREG antibodies?

EREG antibodies exhibit diverse structural and functional properties:

Structural characteristics:

• Available in various formats (monoclonal, polyclonal, humanized)

• Target different epitopes across the EREG protein

• May recognize both pro-EREG (membrane-anchored precursor) and mature (cleaved) EREG

• Species reactivity varies (human-specific, mouse-specific, or cross-reactive)

• Can be produced with different conjugates for various detection methods

Functional characteristics:

• Binding affinity ranges from low nanomolar to subnanomolar (e.g., H231 with Kd = 0.01 μg/ml or 0.1 nmol/L)

• Internalization capacity varies between clones (crucial for ADC development)

• Some antibodies can neutralize EREG-EGFR interactions

• Ability to induce antibody-dependent cellular cytotoxicity (ADCC)

• Framework mutations can dramatically impact binding properties

How does experimental validation of EREG antibodies differ from other growth factor antibodies?

EREG antibody validation presents unique challenges compared to other growth factor antibodies:

• EREG shares structural homology with other EGF family members, necessitating rigorous specificity testing

• The presence of both membrane-bound pro-EREG and soluble mature EREG requires verification that antibodies recognize the appropriate form

• EREG undergoes post-translational modifications, including glycosylation at multiple sites (N47, N57, N90), which may affect antibody recognition

• Expression levels vary significantly across tissues and cancer types, requiring careful selection of positive and negative controls

• Antibodies targeting different epitopes can exhibit substantially different staining patterns despite targeting the same protein

How can I optimize EREG antibody-based Western blot analysis?

Optimizing Western blot analysis with EREG antibodies requires attention to several technical considerations:

Sample preparation:

• Include protease inhibitors to prevent EREG degradation

• For membrane-anchored pro-EREG, use membrane fraction isolation techniques

• Consider deglycosylation treatments if glycosylation interferes with detection

Electrophoresis and transfer:

• EREG typically runs at approximately 19 kDa, but glycosylated forms may appear at higher molecular weights

• Use gradient gels (10-20%) to optimize resolution of this relatively small protein

• Employ wet transfer methods with methanol-containing buffers for efficient transfer

Detection optimization:

• Titrate primary antibody concentrations (typically 0.1-1 μg/ml)

• Validate specificity using recombinant EREG protein as positive control

• Include EREG overexpression and knockout controls when possible

• For low abundance samples, consider enhanced chemiluminescence or fluorescent detection systems

Controls and validation:

• Include positive controls (cell lines with confirmed EREG expression)

• Use negative controls (EREG-negative cell lines or EREG knockdown samples)

• Verify band specificity through peptide competition assays

What methodological considerations are critical for EREG immunohistochemistry (IHC)?

Successful EREG IHC requires optimization across multiple parameters:

Tissue processing and antigen retrieval:

• Optimal fixation: 10% neutral buffered formalin for 24-48 hours

• Antigen retrieval methods should be empirically determined (citrate buffer pH 6.0 or EDTA buffer pH 9.0)

• Heat-induced epitope retrieval is typically more effective than enzymatic methods

Antibody selection and validation:

• Compare multiple antibodies targeting different EREG epitopes

• Validate with known EREG-positive and EREG-negative tissues

• Consider dual staining with different EREG antibodies to confirm specificity

Scoring and interpretation:

• Implement standardized scoring systems combining intensity and percentage of positive cells

• For clinical research, a validated scoring system includes multiplying percentage of positive cells by staining intensity to produce an EREG immunohistochemical score (0-4 = low expression; 6-9 = high expression)

• Document membrane and cytoplasmic staining patterns separately

Technical validation:

• Include isotype controls to assess non-specific binding

• Implement batch controls for multi-sample studies

• Consider automated staining platforms for consistency across samples

How can I effectively use EREG antibodies for studying receptor interactions?

When investigating EREG-receptor interactions, consider these methodological approaches:

Co-immunoprecipitation studies:

• Use antibodies that don't interfere with receptor binding domains

• Implement crosslinking approaches for transient interactions

• Include appropriate detergent conditions to maintain protein-protein interactions

• Validate with reciprocal pull-downs (EREG vs. receptor antibodies)

Functional blocking studies:

• Select antibodies that neutralize EREG-EGFR/ERBB4 interactions

• Validate blocking activity through phosphorylation assays of downstream targets (ERK, AKT)

• Include dose-response experiments to determine IC50 values

• Compare effects on different EGFR family receptors (EGFR vs. ERBB4)

Live-cell binding studies:

• Use non-permeabilizing conditions to assess cell-surface interactions

• Implement FRET or BRET approaches for real-time interaction studies

• Consider antibodies targeting different epitopes to map interaction domains

• Validate with receptor-specific inhibitors or genetic approaches

Research has demonstrated that EREG directly associates with EGFR, requiring EGFR domains I and III and the N57 residue of EREG for binding . This information can guide selection of appropriate antibodies that don't interfere with these critical interaction domains.

How do EREG antibodies help elucidate cancer cell plasticity and drug resistance?

EREG antibodies provide critical insights into cancer cell plasticity and treatment resistance:

Investigation of cancer stem cells (CSCs):

• EREG antibodies can identify and isolate CSC populations with high EREG expression

• Functional studies with neutralizing EREG antibodies can assess the role of EREG in maintaining stemness

• Combined with lineage markers, EREG antibodies help track transitions between differentiated and undifferentiated states

Drug resistance mechanisms:

• EREG antibodies enable monitoring of EREG upregulation following treatment

• Co-staining with phospho-specific antibodies reveals pathway reactivation

• Sequential tissue samples can track EREG expression changes during treatment and progression

Therapeutic targeting:

• EREG antibody-drug conjugates (ADCs) can specifically target resistant cell populations

• EREG antibodies with ADCC activity provide additional killing mechanisms

• Combination approaches with pathway inhibitors can prevent resistance emergence

Research has demonstrated that cancer stem cells exhibit plasticity or the ability to transition between differentiated and undifferentiated states to evade treatment and promote tumor progression, with EREG highly expressed in both states . EREG knockout in colorectal cancer cell lines resulted in significant tumor inhibition in vivo, highlighting its potential as a therapeutic target .

What is the relationship between EREG expression and response to targeted therapies in different cancer types?

EREG expression has complex relationships with treatment response across cancer types:

Colorectal cancer (CRC):

• High EREG expression predicts benefit from anti-EGFR therapy in RAS wildtype patients

• EREG antibodies help identify patients likely to respond to EGFR inhibitors

• EREG expression remains elevated in both RAS wildtype and mutant tumors, but therapeutic implications differ

Head and neck squamous cell carcinoma (HNSCC):

• Upregulated EREG predicts poor prognosis and promotes oncogenic transformation by activating EGFR signaling

• High EREG expression associates with erlotinib response in HNSCC models

• EREG overexpression can mimic EGFR mutations by sustaining EGFR-Erk pathway activation

Resistance mechanisms across cancer types:

• EREG induction can drive adaptive resistance to various targeted therapies

• Sustained EGFR pathway activation via EREG can bypass inhibition at the receptor level

• Combined inhibition of EREG and downstream pathways may overcome resistance

Research has demonstrated that unlike other EGFR ligands, EREG can mimic EGFR mutations by sustaining the activation of the EGFR-Erk pathway, and high EREG expression positively associates with response to treatment with the EGFR inhibitor erlotinib .

How can EREG antibodies be leveraged to study tumor immune microenvironment?

EREG antibodies provide valuable tools for investigating tumor-immune interactions:

Multiplex immunofluorescence applications:

• Co-staining with immune cell markers reveals spatial relationships between EREG-expressing and immune cells

• Quantitative analysis can correlate EREG expression patterns with immune infiltration

• Single-cell resolution approaches can identify specific cellular sources of EREG

Functional immunological studies:

• EREG neutralizing antibodies can assess its role in immune cell recruitment and activation

• Ex vivo culture systems with EREG antibody treatment can examine effects on immune cell function

• Combination with immune checkpoint blockade can evaluate synergistic potential

Translational implications:

• EREG expression correlates with immune checkpoint gene expression across tumor types

• EREG antibody-based assays may help predict response to immunotherapy

• Tumor Immune Dysfunction and Exclusion (TIDE) scores may correlate with EREG expression patterns

Research has demonstrated that in almost all tumor types, EREG expression relates to immune cell infiltration, immune checkpoint gene expression, and immunotherapy response potential .

What strategies are employed for humanizing EREG antibodies for therapeutic applications?

Humanization of EREG antibodies involves sophisticated approaches:

Variable domain resurfacing:

• Based on three-dimensional structure of the Fv fragment

• Maintains critical binding residues while replacing surface-exposed murine sequences

• Computational modeling guides selection of human framework sequences

Framework selection and CDR grafting:

• Careful selection of human framework regions compatible with binding properties

• Grafting of murine complementarity-determining regions (CDRs) onto human frameworks

• Systematic back-mutation of framework residues critical for antigen binding

Case study from research findings:
A humanized anti-EREG antibody (HM0) initially showed significantly decreased antigen-binding affinity. Molecular modeling identified the framework region residue 49 of the light chain variable region (VL) as latently important to antigen binding. Back mutation of the VL49 residue (tyrosine to histidine) generated the humanized version HM1, which completely restored the binding affinity of its murine counterpart . This demonstrates that even a single framework mutation can be critical for preserving binding properties during humanization.

What methodology is used to develop and characterize EREG antibody-drug conjugates (ADCs)?

Development and characterization of EREG ADCs involve systematic approaches:

Antibody selection criteria:

• High binding affinity (e.g., H231 with Kd = 0.01 μg/ml or 0.1 nmol/L)

• Efficient internalization to lysosomes for payload release

• Cross-species reactivity (human/mouse) to facilitate preclinical studies

• Minimal binding to normal tissues to enhance safety profile

Conjugation chemistry and linker selection:

• Site-specific conjugation via enzymatic methods (e.g., MTGase targeting Q295 sites)

• Evaluation of cleavable linkers (dipeptide vs. tripeptide)

• Optimization of drug-antibody ratio (DAR) for efficacy/safety balance

• Assessment of linker stability in circulation

Comprehensive characterization:

• Binding affinity comparison pre- and post-conjugation

• Mass spectrometry to confirm conjugation homogeneity

• Size-exclusion chromatography to assess aggregation

• Biodistribution studies using 89Zr-labeled antibodies

Efficacy and safety evaluation:

• In vitro potency in diverse cell line panels (IC50 determination)

• Activity in RAS mutant and wildtype models

• Patient-derived xenograft (PDX) models for clinical translation

• Toxicity assessment in relevant animal models

Research has shown that EREG ADCs incorporating tripeptide linkers (e.g., glutamic acid-glycine-citrulline; EGC) demonstrate highest potency in EREG-expressing colorectal cancer cells (IC50s = 0.01-0.50 nmol/L), irrespective of RAS mutations .

How do molecular characteristics of anti-EREG antibodies influence their therapeutic potential?

Multiple molecular factors determine the therapeutic utility of EREG antibodies:

Epitope-specific considerations:

• Antibodies binding the N57 region may interfere with EGFR interaction

• Epitopes on pro-EREG vs. mature EREG affect therapeutic mechanism

• Binding to species-conserved epitopes facilitates preclinical translation

Functional mechanisms:

• Direct neutralization of EREG-EGFR signaling

• Antibody-dependent cellular cytotoxicity (ADCC) potential

• Complement-dependent cytotoxicity capability

• Internalization efficiency (critical for ADC approaches)

Physicochemical properties:

• Thermal stability impacts manufacturing and shelf-life

• Aggregation propensity affects immunogenicity risk

• Charged variants influence pharmacokinetics

• Glycosylation pattern affects effector functions

Research has demonstrated that humanized anti-EREG antibodies can exert potent antibody-dependent cellular cytotoxicity (ADCC), providing an additional mechanism beyond signaling inhibition . Additionally, EREG ADCs have shown the ability to neutralize EGFR pathway activity while delivering cytotoxic payloads, offering dual mechanisms of action .

What controls and validation steps are essential for EREG antibody experiments?

Rigorous validation is critical for generating reliable EREG antibody data:

Genetic validation approaches:

• EREG knockout/knockdown systems as negative controls

• EREG overexpression systems as positive controls

• Gene editing to modify specific epitopes for binding characterization

Biochemical validation:

• Recombinant EREG protein as positive control

• Peptide competition assays to confirm specificity

• Western blot confirmation of expected molecular weight

Application-specific validation:

• For IHC: Tissue microarrays with known EREG expression patterns

• For flow cytometry: Cell lines with different EREG expression levels

• For functional assays: Multiple antibody clones targeting different epitopes

• For ADCs: Non-targeting isotype-matched control ADCs

Species cross-reactivity:

• Validation using both human and mouse EREG if cross-reactivity is claimed

• Epitope mapping to determine conservation across species

• Species-specific positive controls

How can cross-reactivity issues with other EGF family members be addressed?

Managing potential cross-reactivity requires systematic approaches:

Specificity testing:

• ELISA screening against all EGF family members (EGF, TGF-α, AREG, etc.)

• Cell lines expressing individual EGF family members

• Recombinant protein panels for direct binding assessment

Technical approaches to enhance specificity:

• Epitope selection targeting unique EREG regions

• Antibody affinity maturation to increase EREG-specific binding

• Absorption against related proteins to remove cross-reactive antibodies

• Validation in systems with selective knockdown of individual family members

Data interpretation considerations:

• Comparison of staining patterns with multiple anti-EREG antibodies

• Correlation with EREG mRNA expression

• Bioinformatic analysis of potential cross-reactive epitopes

• Discrepancies in results between different antibody clones may indicate cross-reactivity issues

Studies have shown that even antibodies targeting related proteins like AREG can demonstrate significantly different staining patterns due to targeting different epitopes, highlighting the importance of thorough validation .

What methodological factors affect EREG detection sensitivity and reproducibility?

Multiple technical factors influence detection quality and consistency:

Sample preparation variables:

• Fixation conditions (type, duration, temperature)

• Tissue processing methods (paraffin embedding, frozen sections)

• Protein extraction buffers (detergent selection, protease inhibitors)

• Storage conditions (temperature, freeze-thaw cycles)

Antibody-specific variables:

• Batch-to-batch variability

• Optimal working concentration (titration essential)

• Incubation conditions (time, temperature, buffer composition)

• Detection system selection (direct vs. indirect, amplification methods)

Standardization approaches:

• Internal calibration standards

• Standard operating procedures documentation

• Reference standards across experiments

• Automated platforms for consistency

Quantification and analysis:

• Digital image analysis for objective quantification

• Standardized scoring systems

• Statistical analysis of technical replicates

• Meta-analysis across multiple antibody clones

For optimal reproducibility, immunohistochemical detection of EREG should include standardized scoring that combines percentage of positive cells and staining intensity to produce a comprehensive EREG immunohistochemical staining score .

What role do EREG antibodies play in understanding cancer heterogeneity and evolution?

EREG antibodies provide valuable tools for investigating tumor heterogeneity:

Spatial heterogeneity analysis:

• IHC mapping of EREG expression patterns across tumor regions

• Correlation with regional genetic/phenotypic differences

• Identification of EREG-high niches that may drive progression

Temporal evolution studies:

• Serial sampling to track EREG expression changes during treatment

• Analysis of circulating tumor cells for EREG expression

• Correlation with emerging resistance mechanisms

Single-cell applications:

• Flow cytometry to isolate EREG-positive subpopulations

• Single-cell RNA-seq correlation with protein-level EREG detection

• Functional characterization of EREG-high vs. EREG-low subclones

Research has shown that EREG promotes cancer stem cell plasticity and transitions between differentiated and undifferentiated states, contributing to tumor heterogeneity and treatment evasion .

How can researchers integrate EREG antibody data with multi-omics approaches?

Integration of EREG antibody data with other omics platforms enhances research insights:

Correlation with genomic data:

• Association of EREG protein expression with copy number alterations

• Relationship with specific mutations (RAS, BRAF, PIK3CA)

• Epigenetic regulation of EREG expression

Transcriptomic integration:

• Correlation between protein and mRNA expression levels

• Co-expression network analysis to identify EREG-associated pathways

• Isoform-specific expression patterns and antibody recognition

Proteomic contextualization:

• Phosphoproteomic analysis of downstream signaling in EREG-high samples

• Interactome mapping using EREG antibody pull-down combined with mass spectrometry

• Activation state of associated receptors and pathway components

Clinical data integration:

• EREG expression correlation with treatment outcomes

• Multivariate models incorporating EREG and other biomarkers

• Machine learning approaches to identify EREG-associated signatures

Studies have shown high correlation between AREG/EREG mRNA levels and the corresponding protein expression as detected by immunohistochemistry, supporting the validity of integrating these data types .